Email This Article

Headlines & Perspectives
Orexigen to Post Obesity Data in Race With Vivus, Arena
By Adam Feuerstein
01/06/09 - 04:20 PM EST
Orexigen Therapeutics is expected to release the first phase III data on its experimental weight-loss drug Contrave ahead of a key investor presentation Monday.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,464.40 1,110.63 2,176.05 32.79
Oil *
77.05
UP
30.69
UP
4.98
UP
6.87
DOWN
0.38
10 Yr
3.28%
SPDR Gold
116.62
+0.29%
+0.45%
+0.32%
-1.15%
Data delayed 20 minutes

Brokerage Partners